Who are sodium valproate with Clozapine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sodium-valproate-with-clozapine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

sodium valproate with Clozapine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sodium valproate with Clozapine (sodium valproate with Clozapine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic + mood stabilizer combination. Area: Psychiatry.

marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

sodium valproate with Clozapine (sodium valproate with Clozapine) — Shanghai Mental Health Center. This combination pairs sodium valproate (a histone deacetylase inhibitor and GABA enhancer) with clozapine (an atypical antipsychotic) to provide synergistic effects on mood stabilization and antipsychotic activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sodium valproate with Clozapine TARGET	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipsychotic + mood stabilizer combination class)

Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sodium valproate with Clozapine — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-valproate-with-clozapine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab